Friday, October 22, 2021 12:29:14 PM
Scripts for week ending October 15, 2021 - Columbus Day on Monday
Overall drug TRx are -1.0% w/w
Vascepa
TRx 79,080; -2.5% (-1,983) w/w; -13.1% y/y
NRx 35,518; -3.0% (-1,116) w/w; -15.5% y/y
Ref 43,561; -2.0% (-878) w/w; -11.0% y/y
Lovaza (Generic & Brand)
TRx 61,762; -4.2% (-2,707) w/w; -1.3% y/y
NRx 29,788; -5.3% (-1,669) w/w; -6.3% y/y
Ref 31,974; -3.1% (-1,038) w/w; +3.9% y/y
Generic Vascepa
TRx 20,353; +6.3% (+1,205) w/w; As % of total V: 20.5%
NRx 11,597; +5.8% (+639) w/w; As % of total V: 24.6%
Ref 8,756; +6.9% (+566) w/w; As % of total V: 16.7%
Generic Vascepa by Manufacturer
Hikma - TRx 12,853 (+100); Generic share 63.1%; Total V share 12.9%
Reddy - TRx 7,501 (+1,119); Generic share 36.9%; Total V share 7.5%
TRx Vascepa + Generic Vascepa
TRx 99,433; -0.8% (-789)
NRx 47,116; -1.0% (-477)
Ref 52,317; -0.6% (-312)
Overall drug TRx are -1.0% w/w
Vascepa
TRx 79,080; -2.5% (-1,983) w/w; -13.1% y/y
NRx 35,518; -3.0% (-1,116) w/w; -15.5% y/y
Ref 43,561; -2.0% (-878) w/w; -11.0% y/y
Lovaza (Generic & Brand)
TRx 61,762; -4.2% (-2,707) w/w; -1.3% y/y
NRx 29,788; -5.3% (-1,669) w/w; -6.3% y/y
Ref 31,974; -3.1% (-1,038) w/w; +3.9% y/y
Generic Vascepa
TRx 20,353; +6.3% (+1,205) w/w; As % of total V: 20.5%
NRx 11,597; +5.8% (+639) w/w; As % of total V: 24.6%
Ref 8,756; +6.9% (+566) w/w; As % of total V: 16.7%
Generic Vascepa by Manufacturer
Hikma - TRx 12,853 (+100); Generic share 63.1%; Total V share 12.9%
Reddy - TRx 7,501 (+1,119); Generic share 36.9%; Total V share 7.5%
TRx Vascepa + Generic Vascepa
TRx 99,433; -0.8% (-789)
NRx 47,116; -1.0% (-477)
Ref 52,317; -0.6% (-312)
Recent AMRN News
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
